117 related articles for article (PubMed ID: 37565616)
21. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Stampfuss J; Kubitza D; Becka M; Mueck W
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
[TBL] [Abstract][Full Text] [Related]
22. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
[TBL] [Abstract][Full Text] [Related]
23. Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
Metzmann K; Schnell D; Jungnik A; Ring A; Theodor R; Hohl K; Meinicke T; Friedrich C
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):549-63. PubMed ID: 24755124
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and safety profile of desmopressin oral tablet formulations in healthy Chinese subjects under fasting and fed conditions.
Li X; Zhang H; Zhu X; Li C; Chen H; Liu J; Chen G; Wu M; Liu C; Shen Z; Niu J; Liu B; Ding Y
Int J Clin Pharmacol Ther; 2018 Sep; 56(9):434-442. PubMed ID: 30049304
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
26. Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males.
Li J; Tan Y; Li K; Hui AM; Wu Z; Han P; Wei Z; Qiu J; Diao L; Wang X
Adv Ther; 2023 Mar; 40(3):1074-1086. PubMed ID: 36627544
[TBL] [Abstract][Full Text] [Related]
27. Comparative Pharmacokinetics of a Controlled-release Pregabalin Tablet (GLA5PR GLARS-NF1) and an Immediate-release Pregabalin Capsule in Healthy Male Volunteers.
Kim TE; Jeon JY; Gu N; Chang Kwon M; Kim MG
Clin Ther; 2018 Dec; 40(12):2112-2124. PubMed ID: 30497798
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
29. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
30. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and Bioequivalence Evaluation of Two Montelukast Sodium Chewable Tablets in Healthy Chinese Volunteers Under Fasted and Fed Conditions.
Li W; Wang Y; Pei Y; Xia Y
Drug Des Devel Ther; 2021; 15():1091-1099. PubMed ID: 33727797
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects.
Zannikos PN; Smit JW; Stahlberg HJ; Wenge B; Hillewaert VM; Etropolski MS
J Opioid Manag; 2013; 9(4):291-300. PubMed ID: 24353023
[TBL] [Abstract][Full Text] [Related]
33. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers.
Shah J; Wesnes KA; Kovelesky RA; Henney HR
Clin Ther; 2006 Sep; 28(9):1308-17. PubMed ID: 17062304
[TBL] [Abstract][Full Text] [Related]
34. A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
Falchook G; Patnaik A; Richardson DL; Harvey RD; Sharma MR; Hafez N; Hamilton E; Piha-Paul SA; Barve M; Wise-Draper T; Patel MR; Dowlati A; Pascuzzo J; Tang SC; Faltermeier C; Malinowska IA; Shtessel L; Striha A; Potocka E
Clin Ther; 2024 Mar; 46(3):228-238. PubMed ID: 38423866
[TBL] [Abstract][Full Text] [Related]
35. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the effect of 3 different diets on the bioavailability of 2 sustained release theophylline matrix tablets.
Gai MN; Isla A; Andonaegui MT; Thielemann AM; Seitz C
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):565-71. PubMed ID: 9455715
[TBL] [Abstract][Full Text] [Related]
37. Comparative Bioavailability of Metformin Hydrochloride Oral Solution Versus Metformin Hydrochloride Tablets in Fasting Mexican Healthy Volunteers.
Garza-Ocañas L; González-Canudas J; Tamez-de la O E; Badillo-Castañeda C; Gómez-Meza MV; Romero-Antonio Y; Molina-Pérez A; Amador-Hernández AG
Adv Ther; 2019 Feb; 36(2):407-415. PubMed ID: 30565181
[TBL] [Abstract][Full Text] [Related]
38. A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.
Dean E; Banerji U; Schellens JHM; Krebs MG; Jimenez B; van Brummelen E; Bailey C; Casson E; Cripps D; Cullberg M; Evans S; Foxley A; Lindemann J; Rugman P; Taylor N; Turner G; Yates J; Lawrence P
Cancer Chemother Pharmacol; 2018 May; 81(5):873-883. PubMed ID: 29541803
[TBL] [Abstract][Full Text] [Related]
39. An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.
Cheng Y; Liu L; Xue Y; Zhou S; Li Y
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):579-592. PubMed ID: 35657581
[TBL] [Abstract][Full Text] [Related]
40. A Phase 1 Study to Assess the Relative Bioavailability, Food Effect, and Safety of a Tablet Formulation of GSK2838232, a Novel HIV Maturation Inhibitor in Healthy Participants After Single and Repeated Doses.
Johnson M; Jewell RC; Gan J; Dumont E; Burns O; Johns BA
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):972-977. PubMed ID: 32558338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
